# A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

> **NCT04184895** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Allergic to House Dust Mites

## Interventions

- **BIOLOGICAL:** ASP2390
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04184895
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-09
- **Primary completion:** 2022-12-22
- **Final completion:** 2026-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184895, "A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04184895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*